Amgen

BLINCYTO

Manufacturer:

Amgen

Blincyto HCPCS:

J9039

HCPCS Code Descriptor:

Injection, blinatumomab, 1 microgram

Category:

J Code

Blincyto NDCs:

55513-0160-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Blincyto CPT Codes:

Potential CPT administration codes for Blincyto can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Blincyto:

BLINCYTO is an Oncology drug manufactured by Amgen and administered via the Intravenous route of administration. The J Code: J9039 is aligned to the drug BLINCYTO.

ACCESS PRICING AND MORE BY REGISTERING

J9039 Added Date:

January 1, 2016

J9039 Effective Date:

January 1, 2016

J9039 Termination Date:

HCPCS Active

Blincyto billing and coding information can be found through Amgen at the link below:
Blincyto patient assistance information can be found through Amgen Assist at the URL: https://www.amgenassist.com/copay
BLINCYTO prescribing information can be found at the link below:
Information regarding BLINCYTO’s side effects can be found at MedlinePlus